share_log

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Karyopharm週六在ASCO 2024上介紹了SIENDO關於晚期或複發性TP53野生型子宮內膜癌研究的最新探索性亞組分析
Benzinga ·  06/02 14:37

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Karyopharm週六在ASCO 2024上介紹了SIENDO關於晚期或複發性TP53野生型子宮內膜癌研究的最新探索性亞組分析

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論